Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

A. Rinaldi, M. Mian, E. Chigrinova, L. Arcaini, G. Bhagat, U. Novak, P. M. V. Rancoita, C. P. de Campos, F. Forconi, R. D. Gascoyne, F. Facchetti, M. Ponzoni, S. Govi, A. J. M. Ferreri, M. Mollejo, M. A. Piris, L. Baldini, J. Soulier, C. Thieblemont, V. CanzonieriV. Gattei, R. Marasca, S. Franceschetti, G. Gaidano, A. Tucci, S. Uccella, M. G. Tibiletti, S. Dirnhofer, C. Tripodo, C. Doglioni, R. dalla Favera, F. Cavalli, E. Zucca, I. Kwee, F. Bertoni

Research output: Contribution to journalArticlepeer-review

130 Citations (Scopus)


Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gains at 3p, 6p, 18p, and del(6q23) (TNFAIP3/A20), whereas splenic MZLs was associated with del(7q31), del(8p). Nodal MZLs did not show statistically significant differences compared with MALT lymphoma while lacking the splenic MZLs-related 7q losses. Gains of 3q and 18q were common to all 3 subtypes. del(8p) was often present together with del(17p) (TP53). Although del(17p) did not determine a worse outcome and del(8p) was only of borderline significance, the presence of both deletions had a highly significant negative impact on the outcome of splenic MZLs.
Original languageEnglish
Pages (from-to)1595-1604
Number of pages10
Issue number5
Publication statusPublished - 01 Feb 2011


Dive into the research topics of 'Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome'. Together they form a unique fingerprint.

Cite this